A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors

被引：0

作者：

Deva, Sanjeev

Zhou, Caicun

Bishnoi, Sarwan K.

Lau, Peter Kar Han

Tran, Ben

Ba, Yi

Galsky, Matt D.

Wang, Yongsheng

Zhang, Yanqiao

Luo, Suxia

Chang, Victoria

Yu, Cunjing

Zhang, Teresa

Zhang, Heather

Ma, Jiafang

Naicker, Kirsha May

Yap, Timothy A.

机构：

[1] Auckland Hosp, Auckland, New Zealand

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Ashford Canc Ctr Res, Glandore, Australia

[4] Linear Clin Res Ltd, Perth, WA, Australia

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Harbin Med Univ, Dept Gastrointestinal Med Oncol, Canc Hosp, Harbin, Peoples R China

[10] Henan Canc Hosp, Zhengzhou, Peoples R China

[11] BeiGene USA Inc, San Mateo, CA USA

[12] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[13] BeiGene UK Ltd, London, England

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2585

引用

页数：1